Screener
SELLAS Life Sciences Group, Inc. SLS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.13M+60.0% | $4.73M+6.6% | $4.22M-3.3% | $3.87M-25.4% | $3.21M-37.3% | ||
| $4.12M+44.3% | —— | —— | —— | $2.86M— | ||
| $9.25M+52.6% | $8.26M+19.3% | $7.08M-3.4% | $6.87M-9.8% | $6.06M-37.1% | ||
| -$9.25M-52.6% | -$8.26M-19.3% | -$7.08M+3.4% | -$6.87M+9.8% | -$6.06M+37.1% | ||
| $845K+238% | $597K+230% | $292K+32.1% | $272K+80.1% | $250K+216% | ||
| -$8.41M-44.6% | -$7.66M-13.7% | -$6.79M+4.5% | -$6.6M+11.6% | -$5.81M+39.2% | ||
| -$0.05+28.6% | -$0.05+37.5% | -$0.06+40.0% | -$0.07+46.2% | -$0.07+66.7% | ||
| -$9.25M-52.6% | -$8.26M-19.3% | -$7.08M+3.4% | -$6.87M+9.8% | -$6.06M+37.1% |
FAQ
- Is SELLAS Life Sciences Group, Inc. profitable?
- SELLAS Life Sciences Group, Inc. is not currently profitable: it reported a net loss of $29.5M over the trailing twelve months, a -4130.1% net margin.
- What are SELLAS Life Sciences Group, Inc.'s profit margins?
- Gross margin is 90.0% and operating margin is -4195.0%, with a -4130.1% net margin.
- What is SELLAS Life Sciences Group, Inc.'s earnings per share?
- SELLAS Life Sciences Group, Inc.'s diluted EPS over the trailing twelve months is $-0.23.
- Where does SELLAS Life Sciences Group, Inc.'s income statement data come from?
- Every line is extracted from SELLAS Life Sciences Group, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.